Ocumetics Technology Corp., a developer of advanced vision restoration technologies, has announced significant progress in its clinical development program, including positive six-month results from its First-in-Human (FIH) study that support advancement to Group Two surgeries. The company also completed the design of its next-generation accommodating intraocular lens, known as the Ocumetics Lens, which incorporates advancements in manufacturability, surgical performance, and scalability.
The positive six-month follow-up data from Group One patients demonstrated encouraging safety and performance outcomes, with patients reporting meaningful improvements in vision and quality of life. Notably, one patient previously considered legally blind is now qualified to drive. These outcomes have provided the foundation for Ocumetics to proceed to the second group of its FIH study, which remains on track for the third quarter of 2026 in Mexico City under Principal Investigator Dr. Raphael Vasquez.
Manufacturing of the redesigned Ocumetics Lens has commenced with the company’s German partner, Amiplant GmbH. The new lens features a one-piece design, eliminating internal interface materials such as air, water, or oil, and is expected to improve manufacturing consistency and surgical handling. The company has also completed all regulatory requirements necessary to proceed to Group Two patient enrollment.
To fund the next phase of clinical development and accelerate commercialization activities, Ocumetics has launched a financing initiative. Proceeds are expected to support completion of Group Two surgeries, finalize manufacturing and quality verification, advance regulatory programs, and continue strategic partnership discussions. Management has engaged with four of the world’s seven largest ophthalmic companies, with follow-up discussions tentatively scheduled for early Q4 2026 after Group Two one-month patient results become available.
‘The past several months have marked one of the most productive periods in Ocumetics’ history,’ said Dean Burns, President and Chief Executive Officer. ‘With group two surgeries expected to commence during the third quarter of 2026, we believe the Company is entering an important value-creation phase.’
The company believes that positive one-month results from Group Two patients will represent a meaningful value-creation milestone as it advances toward larger clinical studies, regulatory submissions, and eventual commercialization. Ocumetics continues to focus on executing its clinical development strategy and building strategic relationships to support the long-term commercialization of the Ocumetics Lens.
For more information, visit the original press release at NewMediaWire.
This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Ocumetics Advances First-in-Human Study with Positive Six-Month Results, Next-Generation Lens Development.